Felix Baker | $1B+
Get in touch with Felix Baker | Felix J. Baker is a highly influential biotech-focused investor and co-founder of Baker Brothers Advisors, a leading hedge fund specializing in healthcare and biotechnology investing. Through his firm, established in 2000, Felix manages over $20 billion in assets and helped generate an estimated $8 billion gain from early investments in Seagen. A PhD immunologist and Stanford alumnus, he also serves on boards of key biotech companies and contributes to Stanford’s biosciences initiatives.
Disclaimer: This profile is based on publicly available information. No endorsement or affiliation is implied.
Managing Member, Baker Brothers Investments
Felix J. Baker, Ph.D. has served as one of our directors since September 2015 and as chair of our compensation committee and a member of our nominating and governance committee since September 2018. Dr. Baker is a Managing Member of Baker Bros. Advisors LP a biotechnology-focused investment adviser to fund partnerships whose investors are primarily endowments and foundations, which Dr. Baker founded, together with his brother Julian Baker, in 2000. Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school. He also serves on the boards of Kiniksa Pharmaceuticals, Ltd., IGM Biosciences, Inc., Kymera Therapeutics, Inc., and Bicycle Therapeutics plc. Previously he served on the board of Seagen, Inc. from July 2003 through December 2023, and Alexion Pharmaceuticals, Inc. from June 2015 through February 2021.
Baker Brothers Advisors (BBA) is an American hedge fund management firm headquartered in New York. Despite its secretive nature, the firm is a leading biotechnology investor and manages over $20 billion in assets under management (AUM).
Background
BBA was founded in 2000 by brothers Felix and Julian Baker. Their father is Keith Michael Baker, a history professor at Stanford University. Felix graduated from Stanford University with a B.S. in Biology, got a PhD in immunology and completed two years of medical school while Julian graduated from Harvard University with a B.A. in Social studies and then worked in the private equity arm of Credit Suisse First Boston. In 1994, the brothers started managing health care investments for the Laurence Tisch's family who owned the Loews Corporation before creating their own standalone business.[2][3][4][5]
The brothers maintained close ties to the Tisch family and until 2017, the BBA office was in the 667 Madison Avenue skyscraper which was the same one as the Loews Corporation.[2]
Since its inception, BBA has been noted for its secrecy. It has no website and the brothers avoid the press as well as refusal to respond to phone calls for comments on their strategy.[2][5]
Investment strategy
BBA focuses on the biotechnology sector and been noted for its strong returns. Yale University’s charitable foundation had $274 million invested with BBA in 2009 and by 2016 it rose to $1.08 billion, a combination of new money and profits of $393 million. In October 2019, BBA's investment value in two weeks increased by $1.4 billion due to Seagen and BeiGene.[2][3][5] In August 2024, The Wall Street Journal reported that BBA's 25% stake investment in Seagen in 2003 resulted in a windfall gain of $8 billion when in 2023, Pfizer acquired Seagen for $43 billion which was considered one of the largest return on capital investments in the industry. Most of those gains were returned back to investors because it didn't see enough opportunities to deploy all that money at once.[4]
BBA's success has been built on advances in the science of genetics, rise in biotechnology stocks and a period of dealmaking as large biopharmaceutical companies acquire up smaller innovators. BBA relies on talented executives and scientists which are often discovered at companies it invests in and frequently end up on the board of directors in other companies in BBA's portfolio. As of 2019, BBA's top 20 disclosed public company investments eight have at least one board member who are BBA employees. Chief executives for 7 of those 20 companies also serve as board members for other companies that are BBA investments. Some welcome BBA's influence such as Eve Slater who has stated the representatives are very scientifically driven" and "active". Others are more critical of BBA's influence such as RA Capital Management who felt BBA's influence in a now-rejected deal to merge BioCryst Pharmaceuticals with Idera Pharmaceuticals significantly favoured BBA at the expense of other shareholders.
Join UHNWI direct Affiliate Program
Earn Passive Income by Sharing Verified Contact Information of Billionaires, Centi-Millionaires, and Multi-Millionaires on the UHNWI Direct Platform
Maximize your earnings potential by sharing direct and validated contact information of the ultra-wealthy, including billionaires, centi-millionaires, and multi-millionaires. Join the UHNWI Direct platform and tap into a lucrative passive income stream by providing valuable data to those seeking high-net-worth connections. Start earning today with UHNWI Direct.
You may also be interested in reviewing other UHNWIs profiles.
To find the person you want to contact, start typing their name or other relevant tags in the search bar.
Please note: Our database contains over 10,000 direct contacts of UHNWIs, and it is highly likely that the individual you are seeking is already included. However, creating individual profiles for each contact is a meticulous and time-intensive process, So, if you are unable to find the profile of the individual you are looking for, please click here.
Filter by Net Worth: All | Billionaires | Centi-Millionaires | Multi-Millionaires
Filter by Location: All | USA | Canada | Europe | UK | Russia & CIS | Asia | MEIA | Australia | Latin America
Filter by Age: 1920-1930 | 1930-1940 | 1940-1950 | 1950-1960 | 1960-1970 | 1970-1980 | 1980-1990 | 1990-2000
Related People
UHNWI direct
